Hypothalamic-Pituitary Brain Tumor Clinical Trials
Here are the 5 most popular medical studies for
Craniopharyngioma Clinical Trials With No Placebo
View 13 craniopharyngioma medical studies that do not have a placebo group.
Tocilizumab for Craniopharyngioma
This trial is testing a new cancer treatment. Patients with new or recurrent/ progressed craniopharyngioma tumors will be given tocilizumab, a drug that may help shrink the tumor. The study will be conducted in two phases, and patients will be followed for up to 5 years.
Vemurafenib + Cobimetinib for Craniopharyngioma
This trial tests vemurafenib and cobimetinib to treat patients with a certain type of brain tumor. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Standard-Dose Chemotherapy vs High-Dose Chemotherapy for Germ Cell Tumors
This trial is studying how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment.
Frequently Asked Questions
What are the top hospitals conducting undefined research?
In the realm of medical advancements, it's not just adults who benefit from innovative treatments and breakthroughs. Several top-rated hospitals across the United States are actively involved in conducting clinical trials to improve healthcare for children facing undefined conditions. At the forefront is the Children's Hospital of Philadelphia, located in the vibrant city of Philadelphia. With six ongoing trials focused on undefined diseases, this institution is committed to finding solutions for young patients. Similarly, Children's Hospital Colorado in Aurora stands alongside with its own set of six active clinical trials dedicated to dealing with undefined illnesses. In Cincinnati, children receive specialized care at Cincinnati Children's Hospital Medical Center where four current studies aim to unlock new understandings about unspecified conditions affecting youth.
Notably contributing towards pediatric research is Texas Children's Hospital nestled in Houston, a renowned hub for medical innovation and expertise. This esteemed hospital also conducts four active clinical trials seeking answers regarding undefined ailments that impact children’s lives significantly. Lastly, Washingtonl Colorado in Aurora stands alongside with its own set of six active clinical trials dedicated to dealing with undefined illnesses. In Cincinnati, children receive specialized care at Cincinnati Children's Hospital Medical Center where four current studies aim to unlock new understandings about unspecified conditions affecting youth.
Notably contributing towards pediatric research is Texas Children's Hospital nestled in Houston, a renowned hub for medical innovation and expertise. This esteemed hospital also conducts four active clinical trials seeking answers regarding undefined ailments that impact children’s lives significantly. Lastly, Washington D.C.'s very own Children's National Medical Center plays an essential role in advancing pediatric healthcare by undertaking three ongoing clinical trials focusing on undefined diseases among children population.
These respected institutions are paving the way forward when it comes to unraveling mysteries surrounding various unidentified health challenges faced by younger patients throughout different parts of their lives. By participating in these significant endeavors and supporting these trailblazing hospitals' efforts through collaboration or funding we collectively move closer toward ensuring healthier futures for countless children worldwide
Which are the best cities for undefined clinical trials?
When it comes to undefined clinical trials, several cities stand out as leaders in research and development. New York boasts 12 active trials exploring treatments like Intensity-Modulated Radiation Therapy and NCOA1 (SRC1) variant. Philadelphia follows closely behind with 8 ongoing studies focused on interventions such as TIP and DAY101. Houston also holds the distinction of having 8 active trials studying treatments including Setmelanotide and Tocilizumab. Grand Rapids with 7 active trials examining Quality-of-Life Assessment and Intensity-Modulated Radiation Therapy, while Orlando also contributes with its own set of 7 active trials involving therapies like Guided Therapy. These cities offer promising opportunities for individuals seeking participation in undefined clinical trials, advancing medical knowledge and potential breakthroughs in healthcare practices
Which are the top treatments for undefined being explored in clinical trials?
In the realm of clinical trials, there are several standout treatments being explored for undefined conditions. One such treatment is daratumumab, currently involved in six active trials and boasting an impressive 134 all-time trials since its introduction in 2012. Another contender is belantamab mafodotin, with four ongoing trials and a total of 26 all-time breast cancer studies to its name since 2018. Lastly, lenalidomide takes the stage as a seasoned veteran with three active breast cancer trials and an astonishing portfolio of 280 all-time clinical investigations since its initial appearance in 2003. These pioneering treatments offer hope for breakthroughs that could positively impact patients facing undefined conditions worldwide.
What are the most recent clinical trials for undefined?
Recent clinical trials have shown promising developments in the field of undefined conditions, offering potential breakthroughs for patients. One notable study is investigating setemelanotide, a Phase 3 trial that aims to assess its efficacy in treating this condition. Additionally, binimetinib oral tablet (Mektovi) is being studied in a Phase 2 trial as another potential treatment option. Another interesting avenue being explored is tocilizumab, which is undergoing a Phase 2 trial to evaluate its effectiveness for undefined conditions. The ongoing research and advancements seen in these trials provide hope for improved outcomes and better quality of life for individuals affected by this health concern.
What undefined clinical trials were recently completed?
Recently completed clinical trials that have not been defined or specified include a trial sponsored by Washington University School of Medicine in October 2021, investigating Uproleselan for multiple myelomay Washington University School of Medicine in October 2021, investigating Uproleselan for multiple myeloma. Another trial sponsored by the National Cancer Institute (NCI) was completed in September 2021, evaluating mRNA-1273. Additionally, AgenTus Therapeutics concluded a trial for agenT-797 in January 2021. These recent advancements demonstrate ongoing efforts to find innovative treatments for multiple myeloma and offer hope to patients affected by this challenging disease.